| Domain | Best-supported finding | Evidence scope/limitation |
|---|---|---|
| Disease identifier | Duane retraction syndrome 3 with or without deafness is represented in Open Targets as **MONDO_0014880**. (pqac-00000001) | MONDO ID supported; avoid adding unsupported OMIM/Orphanet IDs here. |
| Causal gene | The disease is associated with **MAFB** (**ENSG00000204103**), a large MAF bZIP transcription factor. (pqac-00000001, pqac-00000012) | Association is well supported genetically, but accessible sources here do not provide a full curated variant list. |
| Inheritance | Curated disease-target evidence labels the inheritance pattern as **monoallelic autosomal**. (pqac-00000001) | Penetrance and expressivity are not fully quantified in the accessible evidence set. |
| Disease class | This is a **congenital cranial dysinnervation disorder (CCDD)** affecting ocular motility development. (pqac-00000010, pqac-00000013) | CCDD classification is strong; some broader DRS literature is not specific to MAFB-related DRS3. |
| Core ocular phenotype | General DRS is defined by **abduction limitation**, variable adduction deficit, **globe retraction**, and **palpebral fissure narrowing on adduction**; DRS is an incomitant strabismus. (pqac-00000007, pqac-00000008, pqac-00000009) | These signs are well established for DRS overall; exact frequencies in MAFB-related DRS3 are not available here. |
| Auditory phenotype | DRS3 may occur **with or without deafness**; the key 2016 study title specifically cites **inner-ear defects** in humans and mice. (pqac-00000002, pqac-00000001) | Accessible evidence confirms the auditory/inner-ear association, but detailed audiologic frequencies and subtype breakdown are limited. |
| Developmental mechanism | Best-supported mechanism is **loss of MAFB function** disrupting development/survival of **abducens neurons**, causing **aberrant extraocular muscle innervation** and associated inner-ear defects. (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000013) | Mechanistic chain is supported by human genetics plus mouse data; exact embryonic cell/rhombomere details were not directly accessible. |
| Reported variant example | A reported **heterozygous p.Leu239Pro** MAFB variant lies in the **DNA-binding region** and was described as abolishing **MARE** binding; the same patient also had **FSGS**. (pqac-00000003, pqac-00000004, pqac-00000012) | Important genotype-phenotype example, but may represent overlap with renal phenotype rather than isolated ocular disease. |
| Animal model support | Mouse data support causality: studies cited report that **loss of Mafb function** causes Duane syndrome-like ocular innervation defects and inner-ear abnormalities; mutant mice with p.Leu239Pro show impaired podocyte differentiation. (pqac-00000002, pqac-00000012) | Strong biologic support, but not a complete natural-history model for all human phenotypic variability. |
| Diagnosis | Diagnosis is primarily **clinical ophthalmic assessment** of incomitant strabismus/ocular motility pattern; **MRI** can support cranial nerve and extraocular muscle evaluation; **genetic testing** for MAFB is appropriate in syndromic/familial CCDD evaluation. (pqac-00000009, pqac-00000010) | No disease-specific biomarker or standardized MAFB-only diagnostic algorithm was identified. |
| Management | Current care is **supportive/symptom-directed**, using standard DRS approaches such as refractive/amblyopia management, monitoring, and selected strabismus surgery for abnormal head posture or primary-position deviation. (pqac-00000005, pqac-00000006, pqac-00000007) | Evidence is extrapolated from general DRS management; MAFB-specific treatment studies were not found. |
| Disease-modifying therapy | **No disease-modifying or gene-targeted therapy** was identified for MAFB-related DRS3. (pqac-00000010, pqac-00000012) | Current research emphasis is genetic discovery and mechanism, not interventional trials. |
| Ongoing research | A large **observational** genetics study of strabismus/CCDDs is recruiting (**NCT03059420**). (pqac-00000010) | This is not a therapeutic trial; it supports gene discovery and phenotypic expansion. |


*Table: This table summarizes the most defensible disease-level facts for Duane retraction syndrome 3 with or without deafness using only accessible cited evidence. It is designed as a compact knowledge-base artifact that distinguishes strong findings from current evidence gaps.*